This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodin, S. Articles by DiPaola, R. S. Search for Related Content PubMed PubMed Citation Articles by Goodin, S. Articles by DiPaola, R. S.

State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer

The Cancer Institute of New Jersey, The Dean and Betty Gallo Prostate Cancer Center, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Correspondence: Robert S. DiPaola, M.D., The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA. Telephone: 732-235-7469; Fax 732-235-7493; e-mail: dipaolrs{at}umdnj.edu

Initial therapy for advanced prostate cancer includes androgen ablation by surgical or medical castration. Still, nearly all men with metastases will progress to hormone-refractory prostate cancer (HRPC). Current U.S. Food and Drug Administration-approved agents for the treatment of HRPC include mitoxantrone and estramustine, although the vinca alkaloids and the taxanes have shown promising activity in single-agent phase II trials. Combinations of these agents induce a biochemical response in greater than 50% of patients, but the median duration of response is approximately 6 months. Overall survival of patients treated with these combinations is approximately 18-24 months. Studies are ongoing to develop novel therapies that target specific molecular pathways or mechanisms of chemotherapy resistance. Novel agents under development include growth factor receptor inhibitors, antisense oligonucleotides, bisphosphonates, and cell differentiating agents. Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC.

Key Words. Hormone-refractory prostate cancer • Treatment • Resistance • Taxanes

This article has been cited by other articles:

				C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer Ann. Onc., July 1, 2009; 20(7): 1264 - 1269. [Abstract] [Full Text] [PDF]

				A. Hussain, R. S. DiPaola, A. D. Baron, C. S. Higano, N. S. Tchekmedyian, and A. R. Johri Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer Ann. Onc., March 1, 2009; 20(3): 492 - 497. [Abstract] [Full Text] [PDF]